[Modification of doxorubicin action with artificial hyperglycemia].
Approximately a 1.6-fold increase in the antitumor action of doxorubicin used in combination with artificial hyperglycemia was shown on mice C57B1/6 with hemocytoblastosis La. Artificial hyperglycemia was found to change the doxorubicin pharmacokinetics in the experimental animals evident from increased in antibiotic half-life to 42.3 min against 26.5 min in the controls, the apparent initial concentration of doxorubicin being increased 1.6 times. Accumulation of doxorubicin in the bone marrow cells of the mice did not change with artificial hyperglycemia. It was suggested that the increase in the therapeutic effect of doxorubicin used in combination with artificial hyperglycemia was associated with changes in drug pharmacokinetics.
Moroz
L V
LV
Kabieva
A O
AO
Donenko
F V
FV
Borovkova
N B
NB
D000818:Animals; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005947:Glucose / Q000008:administration & dosage*; D006943:Hyperglycemia / Q000378:metabolism*; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors
D004317:Doxorubicin; D005947:Glucose
Modifikatsiia deĭstviia doksorubitsina iskusstvennoĭ giperglikemieĭ.